An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients With Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Belinostat (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Spectrum Pharmaceuticals
- 16 Oct 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.
- 16 Oct 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2018.
- 04 Apr 2016 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.